2020 will be a big year for ArcherDX, says its CEO on the heels of raising $55 million to advance its companion diagnostics platform—which is intended to make precision medicine an option for patients in earlier stages of disease.
Headquartered in Boulder, CO, the company will use the Series C funds to expand its global footprint and support the registration and launch of its solid tumor companion diagnostic, Stratafide.
The FDA in January granted the company breakthrough designation for the device, which identifies genetic mutations via tissue or blood samples, enabling physicians to select the most appropriate targeted therapy or late-stage… Read more »
UNDERWRITERS AND PARTNERS
